MENU
+Compare
PACB
Stock ticker: NASDAQ
AS OF
Apr 25, 04:59 PM (EDT)
Price
$1.09
Change
-$0.04 (-3.51%)
Capitalization
976.68M

PACB Pacific Biosciences of California Forecast, Technical & Fundamental Analysis

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems... Show more

Industry: #Biotechnology
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PACB with price predictions
Apr 24, 2025

PACB in +11.34% Uptrend, rising for three consecutive days on April 07, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PACB advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on April 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

PACB moved below its 50-day moving average on April 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PACB broke above its upper Bollinger Band on April 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PACB entered a downward trend on April 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.393) is normal, around the industry mean (23.728). P/E Ratio (0.000) is within average values for comparable stocks, (81.831). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.610) is also within normal values, averaging (41.794).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

View a ticker or compare two or three
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PACB is expected to report earnings to fall 4.25% to -19 cents per share on May 08

Pacific Biosciences of California PACB Stock Earnings Reports
Q1'25
Est.
$-0.19
Q4'24
Est.
$-0.20
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.41
Q1'24
Missed
by $0.01
The last earnings report on February 13 showed earnings per share of -20 cents, meeting the estimate of -20 cents. With 9.71M shares outstanding, the current market capitalization sits at 976.68M.
A.I. Advisor
published General Information

General Information

a developer of sequencing system products to help scientists to resolve genetically complex problems

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1305 O’Brien Drive
Phone
+1 650 521-8000
Employees
796
Web
https://www.pacb.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGIFX13.970.19
+1.35%
Baillie Gifford International Alpha 3
PJGZX19.85N/A
N/A
PGIM Jennison Focused Value Z
WFEMX14.36N/A
N/A
WCM Focused Emerging Markets Investor
TRTIX19.12N/A
N/A
T. Rowe Price International Value Eq I
TOWFX15.83N/A
N/A
Towpath Focus Institutional

PACB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
-2.56%
MASI - PACB
58%
Loosely correlated
+2.98%
LAB - PACB
46%
Loosely correlated
-0.81%
AZTA - PACB
45%
Loosely correlated
+5.16%
RVTY - PACB
43%
Loosely correlated
+1.55%
ILMN - PACB
42%
Loosely correlated
+1.78%
More